Mesenbio
- Biotech or pharma, therapeutic R&D
Mesenbio, stemming from the University of York, is advancing regenerative medicine through its innovative extracellular vesicle therapeutics platform, FT-01. This flexible, variable platform unlocks this exciting modality and democratises EVs for broad applications. Our exemplification of this platform is MEV-N01, a rheumatoid arthritis therapeutic which has shown to have pro-regenerative and inflammation-resolving efficacy in vivo.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}